How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,076 results for

Physical Medicine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. ACR-ABS-ACNM-ASTRO-SIR-SNMMI Practice Parameters for Selective Internal Radiation Therapy (SIRT) or Radioembolization for Treatment of Liver Malignancies

AND RESPONSIBILITIES OF PERSONNEL Physicians from various medical specialties are involved at different times in the evaluation and management of patients receiving radioembolization. Multidisciplinary expertise is essential and includes interventional radiology, radiation oncology, nuclear medicine, medical physics, radiation safety, hepatology, gastroenterology, medical oncology, and surgical oncology. Interventional radiologists are responsible for performing the mapping angiogram with or without embolization (...) in medical physics and to be a Qualified Medical Physicist. The ACR strongly recommends that the individual be certified in the appropriate subfield(s) by the American Board of Radiology (ABR), the Canadian College of Physics in Medicine, or by the American Board of Medical Physics (ABMP). PRACTICE PARAMETER 7 SIRT or Radioembolization A Qualified Medical Physicist should meet the ACR Practice Parameter for Continuing Medical Education (CME). (ACR Resolution 17, 1996 – revised in 2012, Resolution 42) [9

2019 Society of Interventional Radiology

122. Bone Health and Bone-targeted Therapies for Prostate Cancer

Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline Guideline Question What therapies that target bone health are effective across all stages of prostate cancer? Target Population Men with prostate cancer. Target Audience Health care professionals, health care administrators, medical or radiation oncologists who treat genitourinary cancer, urologists, radiologists, nuclear medicine physicians, endocrinologists, geriatricians, primary care physicians, osteoporosis experts (...) Center, New York, NY 5 Princess Margaret Cancer Center, University Health Network, and University of Toronto, Toronto, Ontario, Canada 6 Cancer Center of Kansas, Wichita, KS 7 Patient Representative, Woolwich, ME 8 Patient Representative, Los Angeles, CA 9 Washington University School of Medicine, St Louis, MO P.J.S. and J.M.M. were Expert Panel co-chairs. Abstract Section: PURPOSE In 2017, Cancer Care Ontario’s Program in Evidence-Based Care released the Bone Health and Bone-Targeted Therapies

2020 American Society of Clinical Oncology Guidelines

123. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy

, including information on smoking and the use of medication, alcohol and other recreational drugs, in particular androgens, is required. In addition, a focused review of the reproductive system should include any developmental history of undescended testes or other genital abnormalities, pubertal development, prior fertility, erectile function, sexual desire and any history of pelvic surgery, genital trauma or infection. The physical examination must include height and weight (and, if obese, waist (...) Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset

2016 MJA Clinical Guidelines

124. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies Full Text available with Trip Pro

for Endoscopic Surgery (EAES). Surg Endosc 2005; 19: 200-221. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Scheme: General statement for lipid-lowering drugs prescribed as pharmaceutical benefits. (accessed May 2013). Doust J, Sanders S, Shaw J, Glasziou P. Prioritising CVD prevention therapy - absolute risk versus individual risk factors. Aust Fam Physician 2012; 41: 805-809. Bell KJ, Hayen A, Irwig L, et al. When to remeasure cardiovascular risk in untreated people at low (...) Primary prevention of cardiovascular disease: new guidelines, technologies and therapies Primary prevention of cardiovascular disease: new guidelines, technologies and therapies | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login

2013 MJA Clinical Guidelines

125. Atopic dermatitis – Flare prevention and use of adjunctive therapies and approaches Full Text available with Trip Pro

Taxonomy (SORT) developed by editors of the US family medicine and primary care journals (ie, American Family Physician , Family Medicine , Journal of Family Practice , and BMJ USA ). x 6 Ebell, M.H., Siwek, J., Weiss, B.D., Woolf, S.H., Susman, J., Ewigman, B. et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract . 2004 ; 17 : 59–67 | | Evidence was graded using a 3-point scale based on the quality (...) Allergy . 1992 ; 22 : 440–446 | | | Insufficient evidence to recommend Chinese herbal therapy C III x 141 Zhang, W., Leonard, T., Bath-Hextall, F., Chambers, C.A., Lee, C., Humphreys, R. et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev . 2004 ; 4 : CD002291 | , x 142 Hon, K.L., Chan, B.C., and Leung, P.C. Chinese herbal medicine research in eczema treatment. Chin Med . 2011 ; 6 : 17 | | | , x 143 Keane, F.M., Munn, S.E., Vivier, A.W., Higgins, E.M., and Taylor, N.F

2014 American Academy of Dermatology

126. Atopic dermatitis – Treatment with topical therapies Full Text available with Trip Pro

called the Strength of Recommendation Taxonomy developed by editors of the US family medicine and primary care journals (ie, American Family Physician , Family Medicine , Journal of Family Practice , and BMJ USA ). x 6 Ebell, M.H., Siwek, J., Weiss, B.D., Woolf, S.H., Susman, J., Ewigman, B. et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract . 2004 ; 17 : 59–67 | | Evidence was graded using a 3-point scale (...) Dermatol Venereol . 2008 ; 22 : 73–82 | , x 20 Sugarman, J.L. and Parish, L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol . 2009 ; 8 : 1106–1111 | They are approved as 510(k) medical devices based on the assertion that they serve a structural role in skin barrier function and do not exert their effects by any chemical actions. This approval process requires less rigorous clinical efficacy data than that needed for Food

2014 American Academy of Dermatology

127. Standardizing Normal Tissue Contouring for Radiation Therapy Treatment Planning

,wherestructureoverlapsbetween radiation oncologists were as low as 10%, and volume variationshadstandarddeviations upto60%. 12 Establish- ingstandardizednormaltissuecontouringassistswithdose assessment during radiation therapy planning, particularly intheeraofadvancedradiation therapytechniques. Safety In 2011, ASTRO partnered with the American Asso- ciation of Physicists in Medicine to develop the Radiation Oncology Incident Learning System (RO-ILS), the only medical specialty society-sponsored incident learning system (...) Francisco, California; c Medical College of Wisconsin, Milwaukee, Wisconsin; d American Society for Radiation Oncology, Arlington, Virginia; e Emory University, Atlanta, Georgia; f University of Florida, Jacksonville, Florida; g London Health Sciences Centre, London, ON, Canada Received 4 September 2018; revised 29 November 2018; accepted 8 December 2018 Abstract Purpose: Thecomprehensiveidenti?cationanddelineationoforgansatrisk(OARs)arevitaltothe quality of radiation therapy treatment planning

2019 American Society for Radiation Oncology

128. Recovering after radiation therapy: A guide for women

Recovering after radiation therapy: A guide for women A guide for women Recovering after Pelvic Radiation TherapyACKNOWLEDGEMENTS This booklet was conceived and developed by a team from the Centre for Medical Psychology and Evidence-based Decision –making (CeMPED) at the University of Sydney, led by Dr Ilona Juraskova and Ms Fran Lubotzky. We gratefully acknowledge the following people for their valuable input into the development of this resource: Ms Kathryn Nattress who was largely involved (...) be sought by contacting Dr Ilona Juraskova at the address below. Centre for Medical Psychology and Evidence-based Decision-making (CeMPED) Transient bld. F12 School of Psychology The University of Sydney NSW 2006 AustraliaRecovering after Pelvic Radiation Therapy A guide for women2. 3. Contents 0 1 | This booklet and you Why we developed this booklet 5. 2 | Understanding your body Diagrams and information about the female anatomy 6. 3 | Pelvic radiation therapy External pelvic radiation therapy Internal

2015 SickKids Supportive Care Guidelines

129. Recovering after radiation therapy: A guide for women

Recovering after radiation therapy: A guide for women A guide for women Recovering after Pelvic Radiation TherapyACKNOWLEDGEMENTS This booklet was conceived and developed by a team from the Centre for Medical Psychology and Evidence-based Decision–making (CeMPED) at the University of Sydney, led by Dr Fran Lubotzky and Dr Ilona Juraskova. We gratefully acknowledge the following people for their valuable input into the development of this resource: The women with gynaecological and anorectal (...) can occur . I nsufficient pr eparation f or sexual penetration, both physical and psychological, can make this worse. Some women find that sperm stings after radiation therapy and have found that using condoms helps reduce the sting and reduces friction during penetration. Finding more comfortable sexual positions, using extra lubrication, being gentle and patient may all help if pain is experienced during sexual intercourse. To help reduce pain and vaginal tightness some women have found

2015 SickKids Supportive Care Guidelines

130. New patients with hemophilia, starting my child on prophylaxis (regular replacement therapy)

New patients with hemophilia, starting my child on prophylaxis (regular replacement therapy) Prophylaxis treatment options for untreated children with severe hemophilia: starting time and dose This document prepares the clinician to discuss scientific evidence with the patient (or care taker) so they can make an informed decision together. Decision 1: What are the options for when to start prophylaxis? Early: before or at least after the first joint bleed or during the 1st or 2nd year of age (...) an implantable central venous access device (CVAD). 5 Older children might also better accept the infusion and require less time. CVADs are associated with: - high risk of infection: rate of 0.66 per 1,000 catheter-days 6 - of 53 children with CVADs, 30% experienced complications after 18 months 7 - of 15 children with CVADs, 53% had deep vein thrombosis after 5½ years 8 complications need for rigorous training and frequent care 9 limited physical activity (for tunneled CVADs only). 9 6 1 0 6 4 10 8 Early

2014 Cancer Council Australia

131. Radiation Therapy for the Whole-Breast (ASTRO)

force on the recommendation statements was evaluated through a modified Delphi approach adapted from the American Society of Clinical Oncology (ASCO) process. 18 Task force members (except the patient representative) completed an online survey to rate their agreement with the recommendations on a five-point Likert scale, ranging from strongly disagree to strongly agree. The medical physics representative abstained from rating some clinically-focused recommendations, which are designated (...) of approximately 350 cGy. 8 These findings support the conceptual model that CF-WBI does not provide an incremental benefit with regard to either tumor control or normal tissue toxicity compared to HF-WBI. In light of the totality of the evidence, the task force favored HF-WBI regimens of 4250 cGy in 16 fractions or 4000 cGy in 15 fractions, as these are the only two regimens that were administered on consecutive treatment days in the randomized literature. The task force also noted that, in * Medical physics

2019 American Society for Radiation Oncology

132. British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy

Protocols for delivery of photodynamic therapy A successful PDT outcome requires the optimization of apply- ing the appropriate prodrug, drug or photosensitizer, light parameters and oxygen, thereby achieving the mechanism of action intended. The resultant photodynamic reaction at the target cell produces the therapeutic result. PDT utilizes the higher selectivity of the photosensitizer for the target tissue compared with healthy tissue. The topically applied photosen- sitizer prodrugs are converted (...) J, Goslinski T et al. Current status of liposomal porphyrinoid photosensitizers. Drug Discov Today 2013; 18:776–84. 12 An JS, Kim JE, Lee DH et al. 0.5% Liposome-encapsulated 5-amino- levulinic acid (ALA) photodynamic therapy for acne treatment. J Cosmet Laser Ther 2011; 13:28–32. 13 Campbell SM, Morton CA, Alyahya R et al. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photody- namic therapy of nodular basal cell carcinoma. Br J Dermatol 2008; 159:387–93. 14

2019 British Association of Dermatologists

133. Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency

Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency 1 Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency (SPIGFD) Formulated by the UK IGF-1 User’s Group February 2015. Revised February 2018 by Dr Helen Storr, Centre for Endocrinology, William Harvey Research Institute (WHRI), Charterhouse Square, Barts and the London School of Medicine, London EC1A 6BQ. Revision due: February 2021 Scope - To guide UK paediatric endocrinologists who are considering (...) signal transducer and activator of transcription 5B (STAT5B), IGF-1 and PAPP-A2 genes also lead to SPIGFD and short stature. In 2007, SPIGFD (defined as height <-3 SD, serum IGF-1 <2.5 th centile and normal GH) became a European Medicines Agency (EMA) licensed indication for recombinant human IGF-1 therapy (rhIGF-1) in the UK. B. Objective of rhIGF-1 treatment Improvement of adult height in SPIGFD children. C. Diagnosis of SPIGFD 1. Diagnosis of SPIGFD requires measurement of serum IGF-1

2018 British Society for Paediatric Endocrinology and Diabetes

134. CTS Position Statement on the Pharmacological Therapy of COPD

therapy for patients with stable COPD. METHODS: The authors systematically reviewed the relevant literature focusing on randomized controlled trials and when available, systematic reviews of randomized controlled trials. The proposed key messages, based on scienti?c evidence and expert-informed opinion, were agreed upon by a majority consensus. MAIN RESULTS: There is typically a signi?cant delay in seeking medical care by patients with dyspnea, often waiting until symptoms affect the performance (...) be considered. Because the superiority of inhaled triple or dual therapy may not be achieved in every patient, the notion of treatment “step down” may be a consideration in some patients. These patients would be those not demonstrating expected bene?ts or having side effects exceeding bene?ts. In any circumstance, when a physician decides usinga treatment “stepdown”, thisapproachshould beundertaken under closemedical supervision. Individuals with ACO are a population of medical interest, however

2017 Canadian Thoracic Society

135. ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer

. ZhangQ,CaiXW,ZhuZF,etal.Full-dosepemetrexedpluscisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. An- ti-Cancer Drugs. 2015;26:456-463. 20. Koshy M, Malik R, Mahmood U, Rusthoven CG, Sher DJ. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. Pract Radiat Oncol. 2015;5:374-382. 21. KoshyM,MalikR,MahmoodU,HusainZ,WeichselbaumRR,Sher DJ (...) ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer Special Article Palliative thoracic radiation therapy for non- small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation

2018 American Society for Radiation Oncology

136. Renal replacement therapy and conservative management

considered for a transplant if risk factors for poor outcomes have been identified; these may include: lack of social support neurocognitive issues non-adherence (medicines, diet, hospital appointments) poor understanding of process and complexities of treatment poorly controlled mental health conditions or severe mental illness substance misuse or dependence. T o find out why the committee made the recommendations on preparing for renal replacement therapy or conservative management – how to assess (...) Indications for switching or stopping renal replacement therapy 1.5.1 Offer information on all medically appropriate treatment options when discussing switching RRT modality. 1.5.2 Consider switching treatment modality or stopping RRT if medically indicated or if the person (or, where appropriate, their family members or carers) asks. 1.5.3 Plan switching treatment modality or stopping RRT in advance wherever possible. 1.5.4 Do not routinely switch people on peritoneal dialysis to a different treatment

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

137. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) Online Learning For Medical Students Exams/LLL/Certifications Exam Prep Research Research Funding AUA Funding Research Education & Events Online Research Education Courses Research Resources Biorepositories and Other Resources Research Publications Research Career Opportunities Advocacy Scholar & Fellowship Programs Comment Letters & Resources International International Opportunities Annual Meeting Membership Collaborations Academic Exchanges Giving Back Practice Resources Coding and Reimbursement

2018 American Urological Association

138. Chronic Opioid Therapy for Chronic Non-Cancer Pain

that will be used to determine treatment success and shall include, at a minimum: (a) Any change in pain relief; (b) Any change in physical and psychosocial function; and (c) Additional diagnostic evaluations or other planned treatments. (2) After treatment begins the physician should adjust drug therapy to the individual health needs of the patient. The physician shall include indications for medication use on the prescription and require photo identification of the person picking up the prescription in order (...) breathing that can cause death. This is more likely for patients who: o Have sleep apnea or chronic lung disease, o Are on higher opioid doses, o Take more medicine than prescribed, or o Mix opioids with alcohol, other prescription medicines (such as sleep aids, muscle relaxers, and tranquilizers), or street drugs. See also “Prescribing naloxone as preventive rescue medication,” p. 13. • Sedation (sleepiness and sluggishness) can cloud patients’ judgment and slow their reaction time, putting them

2016 Kaiser Permanente Clinical Guidelines

139. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

history of cancer Vaccination in people taking biologics Clinical effectiveness Adverse effects and toxicity of drug therapy Drug withdrawal Physical, psychological, and social functioning Maternal and obstetric outcomes Serious infection, cancer, and tuberculosis (TB) rates Outcomes of previous treatments Disease flare or relapse Searches of Electronic Databases Note from the National Guideline Clearinghouse (NGC) : See the "Availability of Companion Documents" field for the full version (...) with psoriasis requiring systemic therapy if methotrexate and ciclosporin have failed, are not tolerated or are contraindicated (see the National Institute for Health and Care Excellence [NICE] guideline on ) and the psoriasis has a large impact on physical, psychological or social functioning (e.g., Dermatology Life Quality Index [DLQI] or Children's DLQI >10 or clinically relevant depressive or anxiety symptoms) and one or more of the following disease severity criteria apply: The psoriasis is extensive

2017 National Guideline Clearinghouse (partial archive)

140. Dental Management of Pediatric Patients Receiving Chemotherapy, Hematopoietic Cell Transplantation, and/or Radiation Therapy

, alcohol-free oral rinses, and/or oral moistur- izers are recommended. 8,32 Placing a humidifier by bedside at night may be useful. 14 Saliva stimulating drugs are not approved for use in children. Fluoride rinses and gels are recommended highly for caries prevention in these patients. Trismus: Daily oral stretching exercises/physical therapy must continue during radiation treatment. Management of trismus may include prosthetic aids to reduce the severity of fibrosis, AMERICAN ACADEMY OF PEDIATRIC (...) immuno- suppressive therapy which lowers the body’s normal immune response. This can be deliberate as in lowering the immune response to prevent the rejection of an organ or hematopoietic cell transplant* (HCT), or it can be incidental as in a side effect of chemotherapy, radiation therapy, or HCT conditioning. Dental intervention with certain modifications must be done promptly and efficiently, with attention to the patient’s medical history, treatment protocol, and health status. Immunosuppressive

2018 American Academy of Pediatric Dentistry

Guidelines

Guidelines – filter by country